Will GLP-1RAs ultimately succeed in the marketplace for obesity treatments, where other weight loss drugs have failed? In the first of a two-part blog series, we explore their use as a treatment of Type 2 diabetes & obesity.
Is metformin on the way out as a first-line therapy for type 2 diabetes, to be replaced by tirzepatide? We examine new treatments for diabetes and obesity.
More than 1 in 7 American adults has chronic kidney disease (CKD), with the majority of those affected unaware of it. CKD is associated with heart disease, stroke, kidney failure and early death. Chronic kidney care for patients who have progressed to end-stage renal disease (ESRD) or kidney failure — and thus require dialysis —...
Digital technologies are becoming an increasingly important part of modern healthcare. Medical devices have the ability to connect to and communicate with other devices or systems. Not only are new types of devices being created, but many existing devices are being updated with digital capabilities. As a result, the U.S. Food and Drug Administration (FDA)...
Digital technology is becoming increasingly important in the healthcare space. This was clearly reflected by the growing number of companies and events focused on the digital healthcare sector during JP Morgan/Biotech Week in San Francisco and new conferences dedicated to digital technology applications in health and wellness that have been scheduled for 2019. Uses of...
Research presented in June at the American Diabetes Association (ADA) meeting highlighted potential advances for diabetes patients who use drugs in a class called incretin mimetics –specifically GLP-1 (glucagon-like peptide 1) agonists — to help control their blood sugar. Such drugs work by increasing the secretion of insulin from the pancreas, inhibiting glucagon (a hormone...